TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,880,945 | -39.7% | 1,440,644 | +3.5% | 0.00% | -33.3% |
| Q2 2023 | $21,377,382 | -21.9% | 1,391,756 | +14.4% | 0.00% | -25.0% |
| Q1 2023 | $27,360,765 | +118498.9% | 1,216,574 | +10.9% | 0.00% | +33.3% |
| Q4 2022 | $23,070 | -99.9% | 1,097,011 | +3.5% | 0.00% | -25.0% |
| Q3 2022 | $26,128,000 | +5.2% | 1,060,406 | +3.5% | 0.00% | 0.0% |
| Q2 2022 | $24,833,000 | -9.0% | 1,024,925 | -3.2% | 0.00% | +33.3% |
| Q1 2022 | $27,287,000 | -15.7% | 1,058,902 | +1.5% | 0.00% | -25.0% |
| Q4 2021 | $32,383,000 | +35.7% | 1,043,283 | +6.0% | 0.00% | +33.3% |
| Q3 2021 | $23,861,000 | +62.7% | 983,978 | -2.1% | 0.00% | +50.0% |
| Q2 2021 | $14,669,000 | -38.6% | 1,005,439 | +5.0% | 0.00% | -50.0% |
| Q1 2021 | $23,902,000 | +15.7% | 957,246 | +26.3% | 0.00% | +33.3% |
| Q4 2020 | $20,655,000 | – | 757,861 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |